Navigation Links
Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
Date:3/14/2008

MADISON, N.J., March 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that it will present at the Lehman Brothers Eleventh Annual Global Healthcare Conference on Wednesday, March 19, 2008 at 9:30 a.m. Eastern Time. Presenting for Wyeth will be Joseph M. Mahady, Senior Vice President, Wyeth and President, Wyeth Pharmaceuticals.

Wyeth's presentation will be webcast live for investors at http://www.wyeth.com and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NA...nnounced updated results from a Phase II study of ...metastatic to the lung in a poster presentation at...y Meeting held in Miami Beach, Florida, from Novem..."A Phase II Study of Intravenous REOLYSIN (Wild-ty...
(Date:11/6/2009)...nda for Arrowhead’s 2010 Personalized Medici...lace on February 22-24, 2010 in Philadelphia, has ...ll highlight key issues in forming partnerships an...ces. , Minneapolis, MN (P...’s 2010 Personalized Medicine Partnerships ...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
(Date:11/5/2009)...RNewswire/ -- DSM Pharmaceutical Products today an...with Galenix, Saint Jean D,Illac, France, where DS...ring partner for Galenix commercial products on a ...te on business development opportunities co-market...he strength of Galenix in drug product development...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...ION CITY, Calif., June 2 Santen,Pharmaceutical Co...he two,companies have entered into a research and ...r the Japanese and Asian development and,commercia...diseases and,conditions including wet age related ...r edema (DME). Sirolimus, originally known as rapa...
...tic mutations that can affect patient response to ...EASANTON, Calif., June 2 Roche and DxS Ltd. have,... DxS TheraScreen K-RAS,Mutation Test and TheraScre...when considered with other clinically relevant fac...nts likely to benefit from a specific,cancer thera...
... the 44th Annual Meeting of,the American Society o...nted investigating the potential utility of Zevali...replacement for external beam radiations or,supple... non-Hodgkin,s,lymphoma (NHL). Cell Therapeutics, ...n the United States., "These two studies add to t...
Other Biology Technology:Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 2Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 3Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 2Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 3Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 4
(Date:11/9/2009)...peful news is that pediatric survival rates have s...eatments that enable survival often cause infertil...ched puberty currently have an opportunity to pres...atment, they may have their semen frozen and prese... produce sperm, although their testicular tissue c...
(Date:11/9/2009)...Energy (DOE) has announced plans to fund research ...chool of Engineering on technologies that would he...ture and permanent safe storage, or sequestration,...oration with Southern Company, the parent company ...e 2009 American Recovery and Reinvestment Act, the...
(Date:11/9/2009)...is publishing a special issue "Beyond the Origin: ...Darwin,s On the Origin of Species which was publis...nd author of the lead article is Dr. Ulrich Kutsch...y biology at the University of Kassel in Germany. ...ree of charge until 30 December 2009 on Springer,s...
Breaking Biology News(10 mins):For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results 5193 1Growing greener greens 10244 1Growing greener greens 10244 2Growing greener greens 10244 3Drug May Help Colitis Patients Avoid Surgery 58775 1
...es of shepherds and travellers encountering lions,...tales about attacks on flocks and people by these ...most of their former range, but for livestock owne... with lions is a daily reality. Although loss of h...ost the herders close to 1000 US$ per family each ...
...was launched today by the Chinese National Space A...e Xichang Satellite Launch Centre, Sichuan, atop a...first step in the Chinese ambition to land robotic... four mission goals to accomplish. The first is to...orms and outline maps of major lunar geological st...
... Germany-October 24, 2007-Harvard University,s Off... announced an agreement to jointly establish the B...at Harvard,s School of Engineering and Applied Sci...ng strong ties with departments and schools throug...ative, integrated partnership among Harvard and BA...
Other Biology News:Living with lions 2Chang'e-1 -- new mission to Moon lifts off 2BASF and Harvard University announce extensive research collaboration 2
Custom Production Service - Quality from AbD Serotec
Rat Big Endothelin-1 (Big ET-1) EIA Kit from Assay Designs/Stressgen Bioreagents
...ptide Synthesis , 20 Amino Acid length max , MS... to customer for future usage conjugation of pepti... 102 days/each , Pre-immune bleed x1 /each , ...t bleed (app. 5 ml) x1 /each , Production blee...
Mouse Anti-Mouse Qa-1 Monoclonal Antibody, Unconjugated, Clone 6A8.6F10 from Santa Cruz Biotechnology, Inc.
Biology Products: